Côte d'IvoireTuberculosis profile
Population  2014 22 million
Estimates of TB burden * 2014 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 4.8 (3.5–6.3) 22 (16–29)
Mortality (HIV+TB only) 2.4 (1.9–2.9) 11 (8.7–13)
Prevalence  (includes HIV+TB) 48 (26–76) 215 (117–343)
Incidence  (includes HIV+TB) 36 (33–40) 165 (150–179)
Incidence (HIV+TB only) 8.5 (7.5–9.6) 39 (34–43)
         
Case detection, all forms (%) 64 (59–70)    
Estimates of MDR-TB burden * 2014   New   Retreatment
% of TB cases with MDR-TB 2.5 (1.1–4.9) 11 (6.2–16)
MDR-TB cases among notified pulmonary
TB cases
430 (190–830) 150 (85–220)
TB case notifications 2014 New ** Relapse
Pulmonary, bacteriologically confirmed 14 233   898
Pulmonary, clinically diagnosed 2 901    
Extrapulmonary 5 243    
       
Total new and relapse 23 275    
Previously treated, excluding relapses 475    
Total cases notified 23 750    
Among 14 233 new cases:
386 (3%) cases aged under 15 years; male:female ratio: 1.7
Reported cases of RR-/MDR-TB 2014 New Retreatment Total **
Cases tested for RR-/MDR-TB   658 (48%) 786
Laboratory-confirmed RR-/MDR-TB cases     471
Patients started on MDR-TB treatment ***     313
TB/HIV 2014 Number (%)
TB patients with known HIV status 22 108 (93)
HIV-positive TB patients 5 292 (24)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 4 737 (90)
HIV-positive TB patients on antiretroviral therapy (ART) 3 964 (75)
HIV-positive people screened for TB 60 027  
HIV-positive people provided with IPT    
Treatment success rate and cohort size (%) Cohort
New cases registered in 2013 (80) 23 796
Previously treated cases registered in 2013 (64) 1 503
HIV-positive TB cases, all types, registered in 2013    
RR-/MDR-TB cases started on second-line treatment in 2012   0
XDR-TB cases started on second-line treatment in 2012   0
Laboratories 2014  
Smear (per 100 000 population) 0.7
Culture (per 5 million population) 0.5
Drug susceptibility testing (per 5 million population) 0.5
Sites performing Xpert MTB/RIF 5
Is second-line drug susceptibility testing available? Yes, in country
Financing TB control 2015  
National TB programme budget (US$ millions) 2.2
% Funded domestically  
% Funded internationally 44%
% Unfunded 56%
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
*** Includes patients diagnosed before 2014 and patients who were not laboratory-confirmed as having
RR-/MDR-TB
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2016-05-31 Data: www.who.int/tb/data